Adynxx Reports Third Quarter 2019 Financial Results
14 nov. 2019 06h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic
02 oct. 2019 08h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Adynxx Reports Second Quarter 2019 Financial Results
14 août 2019 07h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
22 juil. 2019 06h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...
Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice
12 juin 2019 12h32 HE
|
Adynxx, Inc.
SAN FRANCISCO, June 12, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
Adynxx Announces Payment Date of Special Cash Dividend Previously Announced by Alliqua BioMedical
10 mai 2019 06h00 HE
|
Adynxx, Inc.
Adynxx announces May 29, 2019 as payment date of previously announced special cash dividend of $1.05 per share to former Alliqua shareholders Adynxx confirms intent to consummate the previously...
Adynxx, Inc. Receives Nasdaq Notice of Delisting or Failure to Satisfy an Initial Listing Rule or Standard
09 mai 2019 17h30 HE
|
Adynxx, Inc.
SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq:ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors
06 mai 2019 11h05 HE
|
Alliqua BioMedical, Inc
SAN FRANCISCO, May 06, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
Adynxx Completes Merger with Alliqua BioMedical, Adds Pierre Legault and Matt Ruth to Board of Directors
06 mai 2019 06h00 HE
|
Adynxx, Inc.
SAN FRANCISCO, May 06, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (Nasdaq: ADYX), a clinical-stage biopharmaceutical company leading the development of transcription factor decoy technology and...
Alliqua BioMedical CEO Provides Update to Shareholders
22 avr. 2019 10h06 HE
|
Alliqua BioMedical, Inc
LANGHORNE, Pa., April 22, 2019 (GLOBE NEWSWIRE) -- Dear Shareholder: On January 3rd, I wrote a letter updating you, our shareholders, on the status of events that I thought would affect each of...